INT230-6

· Intensity Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for INT230-6, covering 2021-11-17 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK [Phase 2]

See pricing